Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) was the recipient of a large growth in short interest in July. As of July 15th, there was short interest totalling 291,500 shares, a growth of 67.9% from the June 30th total of 173,600 shares. Based on an average trading volume of 72,000 shares, the days-to-cover ratio is currently 4.0 days. Currently, 1.9% of the shares of the stock are short sold.
Gyre Therapeutics Stock Performance
Shares of NASDAQ GYRE traded up $0.04 during midday trading on Friday, reaching $15.02. 32,302 shares of the stock were exchanged, compared to its average volume of 77,179. Gyre Therapeutics has a 52-week low of $4.80 and a 52-week high of $30.40. The stock has a 50 day moving average price of $12.15 and a 200-day moving average price of $15.31.
Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The company reported $0.04 EPS for the quarter. The firm had revenue of $27.17 million for the quarter. On average, equities analysts anticipate that Gyre Therapeutics will post -0.45 earnings per share for the current year.
Insider Buying and Selling at Gyre Therapeutics
Institutional Investors Weigh In On Gyre Therapeutics
An institutional investor recently bought a new position in Gyre Therapeutics stock. Bank of New York Mellon Corp bought a new position in Gyre Therapeutics, Inc. (NASDAQ:GYRE – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 18,266 shares of the company’s stock, valued at approximately $218,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.
Gyre Therapeutics Company Profile
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Featured Stories
- Five stocks we like better than Gyre Therapeutics
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- 10 Best Airline Stocks to Buy
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.